blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3639833

EP3639833 - FAECALIBACTERIUM FOR USE IN PREVENTION OR TREATMENT OF LIVER FIBROSIS [Right-click to bookmark this link]
Former [2020/17]AGENT FOR THE PREVENTION OR TREATMENT OF FAT-RELATED DISEASES AND/OR INFLAMMATION
[2023/07]
StatusNo opposition filed within time limit
Status updated on  14.06.2024
Database last updated on 28.06.2024
FormerThe patent has been granted
Status updated on  07.07.2023
FormerGrant of patent is intended
Status updated on  14.02.2023
FormerExamination is in progress
Status updated on  20.01.2022
FormerRequest for examination was made
Status updated on  20.03.2020
FormerThe international publication has been made
Status updated on  22.12.2018
Most recent event   Tooltip14.06.2024No opposition filed within time limitpublished on 17.07.2024 [2024/29]
Applicant(s)For all designated states
Biofermin Pharmaceutical Co., Ltd.
1-1-2, Sannomiyacho
Chuo-ku
Kobe-shi, Hyogo 650-0021 / JP
For all designated states
Public University Corporation Yokohama City University
22-2 Seto Kanazawa-ku
Yokohama-shi, Kanagawa 236-0027 / JP
[2020/17]
Inventor(s)01 / KAWAHARA, Tomohiro
c/o BIOFERMIN PHARMACEUTICAL CO. LTD.
Research and Development Division
3-4 Ibukidai Higashimachi 7-chome
Nishi-ku
Kobe-shi Hyogo 651-2242 / JP
02 / TANAKA, Yoshiki
c/o BIOFERMIN PHARMACEUTICAL CO. LTD.
Research and Development Division
3-4 Ibukidai Higashimachi 7-chome
Nishi-ku
Kobe-shi Hyogo 651-2242 / JP
03 / SHIMAKAWA, Masaki
c/o BIOFERMIN PHARMACEUTICAL CO. LTD.
Research and Development Division
3-4 Ibukidai Higashimachi 7-chome
Nishi-ku
Kobe-shi Hyogo 651-2242 / JP
04 / OHNO, Hiroshi
c/o BIOFERMIN PHARMACEUTICAL CO. LTD.
Research and Development Division
3-4 Ibukidai Higashimachi 7-chome
Nishi-ku
Kobe-shi Hyogo 651-2242 / JP
05 / KESSOKU, Takaomi
c/o Public University Corporation Yokohama City
University
3-9 Fukuura
Kanazawa-ku
Yokohama-shi Kanagawa 236-0004 / JP
06 / NAKAJIMA, Atsushi
c/o Public University Corporation Yokohama City
University
3-9 Fukuura
Kanazawa-ku
Yokohama-shi Kanagawa 236-0004 / JP
 [2023/32]
Former [2020/17]01 / KAWAHARA Tomohiro
c/o BIOFERMIN PHARMACEUTICAL CO. LTD.
Research and Development Division
3-4 Ibukidai Higashimachi 7-chome
Nishi-ku
Kobe-shi Hyogo 651-2242 / JP
02 / TANAKA Yoshiki
c/o BIOFERMIN PHARMACEUTICAL CO. LTD.
Research and Development Division
3-4 Ibukidai Higashimachi 7-chome
Nishi-ku
Kobe-shi Hyogo 651-2242 / JP
03 / SHIMAKAWA Masaki
c/o BIOFERMIN PHARMACEUTICAL CO. LTD.
Research and Development Division
3-4 Ibukidai Higashimachi 7-chome
Nishi-ku
Kobe-shi Hyogo 651-2242 / JP
04 / OHNO Hiroshi
c/o BIOFERMIN PHARMACEUTICAL CO. LTD.
Research and Development Division
3-4 Ibukidai Higashimachi 7-chome
Nishi-ku
Kobe-shi Hyogo 651-2242 / JP
05 / KESSOKU Takaomi
c/o Public University Corporation Yokohama City
University
3-9 Fukuura
Kanazawa-ku
Yokohama-shi Kanagawa 236-0004 / JP
06 / NAKAJIMA Atsushi
c/o Public University Corporation Yokohama City
University
3-9 Fukuura
Kanazawa-ku
Yokohama-shi Kanagawa 236-0004 / JP
Representative(s)Kraus & Lederer PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
[N/P]
Former [2023/32]Lederer & Keller Patentanwälte Partnerschaft mbB
Unsöldstraße 2
80538 München / DE
Former [2020/17]Kalhammer, Georg, et al
Lederer & Keller
Patentanwälte Partnerschaft mbB
Unsöldstrasse 2
80538 München / DE
Application number, filing date18818703.315.06.2018
[2020/17]
WO2018JP22865
Priority number, dateJP2017011868616.06.2017         Original published format: JP 2017118686
[2020/17]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018230695
Date:20.12.2018
Language:JA
[2018/51]
Type: A1 Application with search report 
No.:EP3639833
Date:22.04.2020
Language:EN
[2020/17]
Type: B1 Patent specification 
No.:EP3639833
Date:09.08.2023
Language:EN
[2023/32]
Search report(s)International search report - published on:JP20.12.2018
(Supplementary) European search report - dispatched on:EP08.02.2021
ClassificationIPC:A61K35/741, A23L31/00, A23L33/135, A61K8/99, A61P3/04, A61P29/00, C12N1/20
[2020/17]
CPC:
A61K35/741 (EP,US); A23L31/00 (EP); A23L33/135 (EP,US);
A61K8/99 (EP); A61P29/00 (EP); A61P3/04 (EP);
C12N1/20 (EP); A61K2035/115 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/17]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:FAECALIBACTERIUM ZUR VERWENDUNG BEI DER VORBEUGUNG ODER BEHANDLUNG VON LEBERFIBROSE[2023/07]
English:FAECALIBACTERIUM FOR USE IN PREVENTION OR TREATMENT OF LIVER FIBROSIS[2023/07]
French:FAECALIBACTERIUM POUR SON UTILISATION DANS LA PRÉVENTION OU LE TRAITEMENT DE LA FIBROSE HÉPATIQUE[2023/07]
Former [2020/17]MITTEL ZUR PRÄVENTION ODER BEHANDLUNG VON FETTBEDINGTEN ERKRANKUNGEN UND ENTZÜNDUNGEN
Former [2020/17]AGENT FOR THE PREVENTION OR TREATMENT OF FAT-RELATED DISEASES AND/OR INFLAMMATION
Former [2020/17]AGENT POUR LA PRÉVENTION OU LE TRAITEMENT DE MALADIES LIÉES À LA GRAISSE ET/OU DE L'INFLAMMATION
Biological materialThis application mentions deposited biological material, check the file for details
Entry into regional phase20.11.2019Translation filed 
20.11.2019National basic fee paid 
20.11.2019Search fee paid 
20.11.2019Designation fee(s) paid 
20.11.2019Examination fee paid 
Examination procedure20.11.2019Examination requested  [2020/17]
31.08.2021Amendment by applicant (claims and/or description)
19.01.2022Despatch of a communication from the examining division (Time limit: M04)
20.05.2022Reply to a communication from the examining division
17.06.2022Despatch of a communication from the examining division (Time limit: M04)
30.09.2022Reply to a communication from the examining division
15.02.2023Communication of intention to grant the patent
19.06.2023Fee for grant paid
19.06.2023Fee for publishing/printing paid
19.06.2023Receipt of the translation of the claim(s)
Opposition(s)13.05.2024No opposition filed within time limit [2024/29]
Fees paidRenewal fee
16.04.2020Renewal fee patent year 03
27.05.2021Renewal fee patent year 04
26.04.2022Renewal fee patent year 05
29.06.2023Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT09.08.2023
CZ09.08.2023
DK09.08.2023
EE09.08.2023
ES09.08.2023
FI09.08.2023
HR09.08.2023
IT09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SK09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
[2024/26]
Former [2024/23]AT09.08.2023
CZ09.08.2023
DK09.08.2023
EE09.08.2023
ES09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SK09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/22]AT09.08.2023
CZ09.08.2023
DK09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RO09.08.2023
RS09.08.2023
SE09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/20]AT09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RS09.08.2023
SE09.08.2023
SM09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/10]AT09.08.2023
FI09.08.2023
HR09.08.2023
LT09.08.2023
LV09.08.2023
NL09.08.2023
PL09.08.2023
RS09.08.2023
SE09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
PT11.12.2023
Former [2024/09]AT09.08.2023
FI09.08.2023
LT09.08.2023
NL09.08.2023
SE09.08.2023
NO09.11.2023
GR10.11.2023
IS09.12.2023
Former [2024/08]LT09.08.2023
NL09.08.2023
NO09.11.2023
GR10.11.2023
Documents cited:Search[XI]WO2016065279  (SYMBIOTIC HEALTH INC [US]) [X] 1-8 * paragraph [[139]]; claims 32, 38 * * examples 19, 20, 21 *[I] 1-9;
 [XP]WO2017210428  (CRESTOVO LLC [US]) [XP] 1-8 * paragraph [[70]]; claim 17 * * the whole document *;
 [XI]  - EVELIINA MUNUKKA ET AL, "Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice", THE I S M E JOURNAL: MULTIDISCIPLINARY JOURNAL OF MICROBIAL ECOLOGY, United Kingdom, (20170404), vol. 11, no. 7, doi:10.1038/ismej.2017.24, ISSN 1751-7362, pages 1667 - 1679, XP055740197 [X] 1-8 * the whole document * [I] 1-9

DOI:   http://dx.doi.org/10.1038/ismej.2017.24
 [XI]  - LOPEZ-SILES MIREIA ET AL, "Cultured Representatives of Two Major Phylogroups of Human Colonic Faecalibacterium prausnitzii Can Utilize Pectin, Uronic Acids, and Host-Derived Substrates for Growth", BIOSIS, BIOSCIENCES INFOR, (20120101), Database accession no. PREV201200130128, URL: BIOSIS, XP002694537 [X] 1-8 * the whole document * * table 1 * [I] 1-9
 [XI]  - XINYUN QIU ET AL, "Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis", JOURNAL OF CROHN'S AND COLITIS, NL, (20131201), vol. 7, no. 11, doi:10.1016/j.crohns.2013.04.002, ISSN 1873-9946, pages e558 - e568, XP055506802 [X] 1-8 * the whole document * [I] 1-9

DOI:   http://dx.doi.org/10.1016/j.crohns.2013.04.002
International search[XYA]US2015044172  (BICALHO RODRIGO CARVALHO [US], et al) [X] 1, 2, 4-6, 8-10 * (claim 2, paragraphs [0038]-[0041]) & WO 2013/130624 A2 & CN 104363769 A * [Y] 1-6, 8-10 [A] 7;
 [XYA]JP2016511272  (RIJKSUNIVERSITEIT GRONINGEN) [X] 1, 2, 4-6, 8-10 * (claims, paragraphs [0012]-[0016], examples 2-6) & WO 2014/137211 A1 (claims, pp. 45, examples 2-6) & US 2016/0000838 A1 & EP 2988761 A1 & CN 105228635 A & KR 10-2015-0134356 A * [Y] 1-6, 8-10 [A] 7;
 [XYA]JP2016517425  (THERABIOME, LLC) [X] 1, 2, 4-6, 8-10 * (claims 12, 16, paragraphs [0081]-[0083], example 2) & WO 2014/152338 A1 (claims, pp. 26-30, example 2)& US 2016/0022592 A1 & EP 2968187 A1 & CN 105120847 A * [Y] 1-6, 8-10 [A] 7;
 [XYA]WO2016141454  (UNIV BRITISH COLUMBIA [CA]) [X] 1, 2, 4-6, 8-10 * (claims, claims 10, 12, 14, paragraph [0074]) & JP 2018-515426 A & US 2018/0050070 A1 & EP 3268018 A1 & CN 107949393 A * [Y] 1-6, 8-10 [A] 7;
 [XYA]WO2017072278  (METABOGEN AB [SE]) [X] 1, 2, 4-6, 8-10 * (abstract, pp. 20-21, etc.) & GB 201519088 D & CA 3002603 A & AU 2016/344770 A * [Y] 1-6, 8-10 [A] 7;
 [XYA]  - SOKOL, H. et al., "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients", PNAS, (20080000), vol. 105, no. 43, ISSN 0027-8424, pages 16731 - 16736, XP002579466 [X] 1, 2, 4-6, 8-10 * (fig. 2-7) * [Y] 1-6, 8-10 [A] 7

DOI:   http://dx.doi.org/10.1073/PNAS.0804812105
 [XYA]  - MARTIN, R. et al., "Impact of the commensal bacterium Faecalibacterium prausnitzii in a non active inflammation murine model", Gastroenterology, (20130000), vol. 144, no. 5, pages 897 - 898, XP055565421 [X] 1, 2, 4-6, 8-10 * (abstract number Tu1988) (ISSN:00165085) (entire description) * [Y] 1-6, 8-10 [A] 7

DOI:   http://dx.doi.org/10.1016/S0016-5085(13)63344-2
 [XYA]  - DUNCAN, SH. et al., "Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov.", Int J System Evolut Microbiol., (20020000), vol. 52, ISSN 1466-5026, pages 2141 - 2146, XP055565436 [X] 10 * (entire description) * [Y] 3-6 [A] 7

DOI:   http://dx.doi.org/10.1099/ijs.0.02241-0
 [XYA]  - ALTAMIMI, M. et al., "Effect of oligosaccharides on the adhesion of gut bacteria to human HT-29 cells", Anaerobe, (20160000), vol. 39, ISSN 1075-9964, pages 136 - 142, XP029536947 [X] 10 * (entire description) * [Y] 3-6 [A] 7

DOI:   http://dx.doi.org/10.1016/j.anaerobe.2016.03.010
Examination   - HOOSHMAND BABAK ET AL, "Fusobacterium nucleatum: A cause of subacute liver abscesses with extensive fibrosis crossing the diaphragm, mimicking actinomycosis", GERMS, vol. 9, no. 2, doi:10.18683/germs.2019.1164, (20190601), pages 102 - 105, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591525/pdf/germs-09-02-102.pdf, XP055852297

DOI:   http://dx.doi.org/10.18683/germs.2019.1164
    - Garcia-Carretero Rafael ET AL, "Clinical Features and Outcomes of Fusobacterium Species Infections in a Ten-Year Follow-up", The Journal of Critical Care Medicine, vol. 3, no. 4, doi:10.1515/jccm-2017-0029, (20171001), pages 141 - 147, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769905/pdf/jccm-03-141.pdf, XP055852323

DOI:   http://dx.doi.org/10.1515/jccm-2017-0029
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.